{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T17:46:28Z","timestamp":1790444788527,"version":"4.1.0"},"reference-count":58,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T00:00:00Z","timestamp":1737676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","ejinme.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Internal Medicine"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.ejim.2025.01.014","type":"journal-article","created":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T23:52:57Z","timestamp":1737503577000},"page":"55-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"special_numbering":"C","title":["Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: A meta-analysis of randomized controlled trials"],"prefix":"10.1016","volume":"135","author":[{"given":"Renzo","family":"Laborante","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2556-4809","authenticated-orcid":false,"given":"Donato Antonio","family":"Paglianiti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1266-7131","authenticated-orcid":false,"given":"Emiliano","family":"Bianchini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Galli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4878-8146","authenticated-orcid":false,"given":"Josip Andelo","family":"Borovac","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianluigi","family":"Savarese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5404-3968","authenticated-orcid":false,"given":"Giuseppe","family":"Patti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Domenico","family":"D'Amario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0001","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1038\/s41572-020-0151-7","article-title":"Acute heart failure","volume":"6","author":"Arrigo","year":"2020","journal-title":"Nat Rev Dis Primers"},{"issue":"37","key":"10.1016\/j.ejim.2025.01.014_bib0002","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 focused update of the 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.01.014_bib0003","first-page":"pvae047","article-title":"Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials","author":"Laborante","year":"2024","journal-title":"Europ Heart J - Cardiovasc Pharmacother"},{"issue":"10367","key":"10.1016\/j.ejim.2025.01.014_bib0004","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/S0140-6736(22)02076-1","article-title":"Safety, tolerability and efficacy of up-titration of guideline-directed medical therapies for acute heart failure (STRONG-HF): a multinational, open-label, randomised, trial","volume":"400","author":"Mebazaa","year":"2022","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0005","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/bcp.13760","article-title":"The influence of heart failure on the pharmacokinetics of cardiovascular and non-cardiovascular drugs: a critical appraisal of the evidence","volume":"85","author":"Mangoni","year":"2019","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.014_bib0006","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1210\/jc.2019-00139","article-title":"SGLT2 inhibitors increase the risk of diabetic ketoacidosis developing in the community and during hospital admission","volume":"104","author":"Hamblin","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"7","key":"10.1016\/j.ejim.2025.01.014_bib0007","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1002\/ejhf.2888","article-title":"Pre-discharge and early post-discharge management of patients hospitalized for acute heart failure: a scientific statement by the heart failure association of the ESC","volume":"25","author":"Metra","year":"2023","journal-title":"Eur J Heart Fail"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.014_bib0008","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300286","article-title":"Dapagliflozin in myocardial infarction without diabetes or heart failure","volume":"3","author":"James","year":"2024","journal-title":"NEJM Evid"},{"key":"10.1016\/j.ejim.2025.01.014_bib0009","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.014_bib0010","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1007\/s00392-022-02148-2","article-title":"Cardiovascular and renal effects of SGLT2 inhibitor initiation in acute heart failure: a meta-analysis of randomized controlled trials","volume":"112","author":"Carvalho","year":"2023","journal-title":"Clin Res Cardiol"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0011","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000524435","article-title":"Evaluating the initiation of sodium\/glucose cotransporter 2 inhibitors within 2 weeks of an acute hospital admission: a systematic review and meta-analysis of nine clinical trials","volume":"31","author":"Chieng","year":"2022","journal-title":"Med Princ Pract"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0012","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12933-022-01455-2","article-title":"Efficacy and safety of sodium-glucose cotransporter 2 inhibitors initiation in patients with acute heart failure, with and without type 2 diabetes: a systematic review and meta-analysis","volume":"21","author":"Salah","year":"2022","journal-title":"Cardiovasc Diabetol"},{"issue":"7","key":"10.1016\/j.ejim.2025.01.014_bib0013","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.ejim.2025.01.014_bib0014","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The cochrane collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"Bmj"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.014_bib0015","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.cegh.2018.05.005","article-title":"Interpretation of subgroup analyses in systematic reviews: a tutorial","volume":"7","author":"Richardson","year":"2019","journal-title":"Clin Epidemiol Glob Health"},{"issue":"32","key":"10.1016\/j.ejim.2025.01.014_bib0016","doi-asserted-by":"crossref","first-page":"E901","DOI":"10.1503\/cmaj.200077","article-title":"Development of the instrument to assess the credibility of effect modification analyses (ICEMAN) in randomized controlled trials and meta-analyses","volume":"192","author":"Schandelmaier","year":"2020","journal-title":"Cmaj"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0017","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1471-2288-14-25","article-title":"The Hartung-Knapp-Sidik-Jonkman method for random effects meta-analysis is straightforward and considerably outperforms the standard DerSimonian-Laird method","volume":"14","author":"IntHout","year":"2014","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.ejim.2025.01.014_bib0018","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2020.602251","article-title":"Safety and efficacy of adding dapagliflozin to furosemide in type 2 diabetic patients with decompensated heart failure and reduced ejection fraction","volume":"7","author":"Ibrahim","year":"2020","journal-title":"Front Cardiovasc Med"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.014_bib0019","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1056\/NEJMoa2030183","article-title":"Sotagliflozin in patients with diabetes and recent worsening heart failure","volume":"384","author":"Bhatt","year":"2021","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.014_bib0020","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/ejhf.1713","article-title":"Randomized, double-blind, placebo-controlled, multicentre pilot study on the effects of empagliflozin on clinical outcomes in patients with acute decompensated heart failure (EMPA-RESPONSE-AHF)","volume":"22","author":"Damman","year":"2020","journal-title":"Eur J Heart Fail"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0021","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.120.007048","article-title":"Effect of empagliflozin as an add-on therapy on decongestion and renal function in patients with diabetes hospitalized for acute decompensated heart failure: a prospective randomized controlled study","volume":"14","author":"Tamaki","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0022","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/s41591-021-01659-1","article-title":"The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial","volume":"28","author":"Voors","year":"2022","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0023","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000529614","article-title":"Impact of dapagliflozin treatment on serum sodium concentrations in acute heart failure","volume":"13","author":"Charaya","year":"2023","journal-title":"Cardiorenal Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0024","doi-asserted-by":"crossref","DOI":"10.1136\/openhrt-2021-001936","article-title":"Impact of dapagliflozin treatment on renal function and diuretics use in acute heart failure: a pilot study","volume":"9","author":"Charaya","year":"2022","journal-title":"Open Heart"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.014_bib0025","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1161\/CIRCULATIONAHA.122.059038","article-title":"Effects of early empagliflozin initiation on diuresis and kidney function in patients with acute decompensated heart failure (EMPAG-HF)","volume":"146","author":"Schulze","year":"2022","journal-title":"Circulation"},{"issue":"14","key":"10.1016\/j.ejim.2025.01.014_bib0026","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1016\/j.jacc.2022.07.021","article-title":"Dapagliflozin in patients recently hospitalized with heart failure and mildly reduced or preserved ejection fraction","volume":"80","author":"Cunningham","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ejim.2025.01.014_bib0027","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ijcard.2023.03.002","article-title":"Impact of dapagliflozin on cardiac function following anterior myocardial infarction in non-diabetic patients - DACAMI (a randomized controlled clinical trial)","volume":"379","author":"Dayem","year":"2023","journal-title":"Int J Cardiol"},{"issue":"31","key":"10.1016\/j.ejim.2025.01.014_bib0028","doi-asserted-by":"crossref","first-page":"2966","DOI":"10.1093\/eurheartj\/ehad341","article-title":"Dapagliflozin vs. metolazone in heart failure resistant to loop diuretics","volume":"44","author":"Yeoh","year":"2023","journal-title":"Eur Heart J"},{"key":"10.1016\/j.ejim.2025.01.014_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2023.176179","article-title":"The clinical outcomes of dapagliflozin in patients with acute heart failure: a randomized controlled trial (DAPA-RESPONSE-AHF)","volume":"961","author":"Emara","year":"2023","journal-title":"Eur J Pharmacol"},{"issue":"14","key":"10.1016\/j.ejim.2025.01.014_bib0030","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1016\/j.jacc.2024.02.009","article-title":"Efficacy and safety of dapagliflozin in patients with acute heart failure","volume":"83","author":"Cox","year":"2024","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ejim.2025.01.014_bib0031","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/j.jchf.2023.01.018","article-title":"Recency of heart failure hospitalization, outcomes, and the effect of empagliflozin: an EMPEROR-pooled analysis","volume":"11","author":"Ferreira","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"16","key":"10.1016\/j.ejim.2025.01.014_bib0032","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1056\/NEJMoa2314051","article-title":"Empagliflozin after acute myocardial infarction","volume":"390","author":"Butler","year":"2024","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0033","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jchf.2022.08.009","article-title":"Heart failure drug treatment-inertia, titration, and discontinuation: a multinational observational study (EVOLUTION HF)","volume":"11","author":"Savarese","year":"2023","journal-title":"JACC Heart Fail"},{"issue":"13","key":"10.1016\/j.ejim.2025.01.014_bib0034","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029071","article-title":"Eligibility for the 4 pharmacological pillars in heart failure with reduced ejection fraction at discharge","volume":"12","author":"D'Amario","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.ejim.2025.01.014_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/S0735-1097(24)02316-7","article-title":"Eligibility and projected benefits of rapid initiation of quadruple medical therapy for newly diagnosed heart failure","author":"Greene","year":"2024","journal-title":"JACC: Heart Fail"},{"key":"10.1016\/j.ejim.2025.01.014_bib0036","article-title":"Physician perceptions, attitudes, and strategies towards implementing guideline-directed medical therapy in heart failure with reduced ejection fraction. A survey of the heart failure association of the ESC and the ESC council for cardiology practice","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.01.014_bib0037","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3295","article-title":"How to tackle therapeutic inertia in heart failure with reduced ejection fraction. A scientific statement of the heart failure association of the ESC","author":"Savarese","year":"2024","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.ejim.2025.01.014_bib0038","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.ejim.2020.05.044","article-title":"Impact of acute kidney injury on in-hospital outcomes among patients hospitalized with acute heart failure - a propensity-score matched analysis","volume":"79","author":"Shetty","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0039","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s40264-017-0602-6","article-title":"Can SGLT2 inhibitors cause acute renal failure? Plausible role for altered glomerular hemodynamics and medullary hypoxia","volume":"41","author":"Szalat","year":"2018","journal-title":"Drug Saf."},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0040","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.dsx.2020.02.012","article-title":"Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: a systematic review and meta-analysis of cardio-vascular outcome trials","volume":"14","author":"Singh","year":"2020","journal-title":"Diabete Metab Synd: Clin Res Rev"},{"key":"10.1016\/j.ejim.2025.01.014_bib0041","doi-asserted-by":"crossref","DOI":"10.1002\/ejhf.3284","article-title":"Differences in presentation, diagnosis and management of heart failure in women. A scientific statement of the heart failure association of the ESC","author":"Rosano","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1111\/j.1463-1326.2011.01517.x","article-title":"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors","volume":"14","author":"Grempler","year":"2012","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.ejim.2025.01.014_bib0043","doi-asserted-by":"crossref","first-page":"F1343","DOI":"10.1152\/ajprenal.00007.2015","article-title":"Modeling oxygen consumption in the proximal tubule: effects of NHE and SGLT2 inhibition","volume":"308","author":"Layton","year":"2015","journal-title":"Am J Physiol Renal Physiol"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.014_bib0044","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1111\/dom.12917","article-title":"Sodium-glucose co-transporter-2 inhibitors and risk of adverse renal outcomes among patients with type 2 diabetes: a network and cumulative meta-analysis of randomized controlled trials","volume":"19","author":"Tang","year":"2017","journal-title":"Diabetes Obes Metab"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0045","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1186\/s12933-023-01970-w","article-title":"Left ventricular remodeling response to SGLT2 inhibitors in heart failure: an updated meta-analysis of randomized controlled studies","volume":"22","author":"Carluccio","year":"2023","journal-title":"Cardiovasc Diabetol"},{"issue":"3","key":"10.1016\/j.ejim.2025.01.014_bib0046","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1002\/ejhf.2103","article-title":"Temporal trends in mortality and readmission after acute heart failure: a systematic review and meta-regression in the past four decades","volume":"23","author":"Kimmoun","year":"2021","journal-title":"Eur J Heart Fail"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.014_bib0047","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.121.008335","article-title":"Trends in 30- and 90-day readmission rates for heart failure","volume":"14","author":"Khan","year":"2021","journal-title":"Circ Heart Fail"},{"issue":"5","key":"10.1016\/j.ejim.2025.01.014_bib0048","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.9305","article-title":"Comparative outcomes of empagliflozin to dapagliflozin in patients with heart failure","volume":"7","author":"Modzelewski","year":"2024","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ejim.2025.01.014_bib0049","doi-asserted-by":"crossref","first-page":"5915","DOI":"10.2147\/IJGM.S366943","article-title":"Dapagliflozin and empagliflozin in heart failure with reduced ejection fraction: a retrospective study","volume":"15","author":"Hao","year":"2022","journal-title":"Int J Gen Med"},{"issue":"10354","key":"10.1016\/j.ejim.2025.01.014_bib0050","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(22)01429-5","article-title":"SGLT-2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials","volume":"400","author":"Vaduganathan","year":"2022","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ejim.2025.01.014_bib0051","article-title":"Bleeding complications in patients undergoing percutaneous coronary intervention","volume":"23","author":"Galli","year":"2022","journal-title":"RCM"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.014_bib0052","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1002\/ejhf.3129","article-title":"The effect of sodium-glucose cotransporter 2 inhibitors on left cardiac remodelling in heart failure with reduced ejection fraction: systematic review and meta-analysis","volume":"26","author":"Usman","year":"2024","journal-title":"Eur J Heart Fail"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0053","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/s13098-022-00951-5","article-title":"The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial","volume":"14","author":"Gohari","year":"2022","journal-title":"Diabetol Metab Syndr"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0054","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.121.022761","article-title":"Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Dapagliflozin Stabilizes Diabetes-Induced Atherosclerotic Plaque Instability","volume":"11","author":"Chen","year":"2022","journal-title":"J Am Heart Assoc"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0055","doi-asserted-by":"crossref","first-page":"17937","DOI":"10.1038\/s41598-019-54224-9","article-title":"Glucose lowering by SGLT2-inhibitor empagliflozin accelerates atherosclerosis regression in hyperglycemic STZ-diabetic mice","volume":"9","author":"Pennig","year":"2019","journal-title":"Sci Rep"},{"issue":"4","key":"10.1016\/j.ejim.2025.01.014_bib0056","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s00125-020-05359-2","article-title":"Sodium-glucose cotransporter 2 inhibitors reduce myocardial infarct size in preclinical animal models of myocardial ischaemia-reperfusion injury: a meta-analysis","volume":"64","author":"Sayour","year":"2021","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.ejim.2025.01.014_bib0057","doi-asserted-by":"crossref","first-page":"9587","DOI":"10.1038\/s41598-018-28027-3","article-title":"Acute heart failure developed as worsening of chronic heart failure is associated with increased mortality compared to de novo cases","volume":"8","author":"Degoricija","year":"2018","journal-title":"Sci Rep"},{"issue":"2","key":"10.1016\/j.ejim.2025.01.014_bib0058","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1007\/s11121-013-0377-7","article-title":"Meta-analysis and subgroups","volume":"14","author":"Borenstein","year":"2013","journal-title":"Prev Sci"}],"container-title":["European Journal of Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500024X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S095362052500024X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T16:35:02Z","timestamp":1746203702000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S095362052500024X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":58,"alternative-id":["S095362052500024X"],"URL":"https:\/\/doi.org\/10.1016\/j.ejim.2025.01.014","relation":{},"ISSN":["0953-6205"],"issn-type":[{"value":"0953-6205","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and efficacy of early initiation of sodium-glucose co-transporter inhibitors 2 in patients hospitalized for acute heart failure: A meta-analysis of randomized controlled trials","name":"articletitle","label":"Article Title"},{"value":"European Journal of Internal Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejim.2025.01.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V. on behalf of European Federation of Internal Medicine.","name":"copyright","label":"Copyright"}]}}